Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Velinotamig specified dose on specified days., Velinotamig specified dose on specified days
Velinotamig · 1 trial · 2 indications
Incidence and severity of all adverse events, serious adverse events, adverse events of special interest, adverse events leading to treatment discontinuation, and laboratory abnormalities.
| Arm | Type | Description |
|---|---|---|
| Part A: Dose Escalation. | EXPERIMENTAL | Patients with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia with velinotamig in dose escalation cohorts. |
| Part B: Dose Expansion. | EXPERIMENTAL | Patients with relapsing and refractory immune thrombocytopenia and warm autoimmune hemolytic anemia with velinotamig in dose expansion cohorts. |
| Name | Type | Description |
|---|---|---|
| Velinotamig specified dose on specified days. | DRUG | Velinotamig is an engineered bispecific antibody directed against BCMA and CD3. |
Inclusion Criteria: * Age ≥18 to 80 years * Active autoimmune cytopenia * Relapsed/refractory after standard of care therapy * ECOG performance status 2 or lower Laboratory parameters including the following: * Absolute lymphocyte count (ALC) ≥0.5 × 109/L * Absolute neutrophil count (ANC) ≥1.0 × ...